Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Myriad Genetics Q1 2024 Adj EPS $(0.01) Beats $(0.10) Estimate, Sales $202.200M Beat $193.506M Estimate

Author: Benzinga Newsdesk | May 07, 2024 05:22pm
Myriad Genetics (NASDAQ:MYGN) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.10) by 90 percent. This is a 95.24 percent increase over losses of $(0.21) per share from the same period last year. The company reported quarterly sales of $202.200 million which beat the analyst consensus estimate of $193.506 million by 4.49 percent. This is a 11.59 percent increase over sales of $181.200 million the same period last year.

Posted In: MYGN


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist